A Phase 3 Trial Investigating Blinatumomab (IND#117467 NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma(B-LLy)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Standard Risk Or Down Syndrome B Lymphoblastic Leukemia (b-all) And Localized B-lymphoblastic Lymphoma (b-lly)
  • Age: Between 1 Year(s) - 31 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) B-ALL patients without DS must have an initial white blood cell count <50,000/µL. 2) B-ALL patients with DS are eligible regardless of the presenting white blood cell count.

You may not be eligible for this study if the following are true:

  • 1) Patient must not have secondary ALL that developed after treatment of a prior malignancy with cytotoxic chemotherapy. 2) Patient must not have acute undifferentiated leukemia(AUL

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.